BR9612136A - Acidos hidroxâmicos arilsulfonamido substituídos por alfa como tnf-alfa e inibidores de metaloproteínase de matriz - Google Patents

Acidos hidroxâmicos arilsulfonamido substituídos por alfa como tnf-alfa e inibidores de metaloproteínase de matriz

Info

Publication number: BR9612136A
Authority: BR; Brazil
Prior art keywords: alpha; tnf; matrix metalloproteinase; metalloproteinase inhibitors; hydroxamic acids
Prior art date: 1995-12-15

Application number

BR9612136A

Other languages

English (en)

Other versions

BR9612136B1 (pt

Inventor

David Thomas Parker

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-15

Filing date

1996-12-03

Publication date

1999-07-13

1996-12-03 Application filed by Novartis Ag filed Critical Novartis Ag

1999-07-13 Publication of BR9612136A publication Critical patent/BR9612136A/pt

2010-11-30 Publication of BR9612136B1 publication Critical patent/BR9612136B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI9612136-0A 1995-12-15 1996-12-03 ácidos arilsulfonamido substituìdos por alfa como inibidores de tnf-alfa hidroxámicos, alfa- de matriz de metaloproteinase, bem como composição farmacêutica compreendendo os mesmos. BR9612136B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US866195P	1995-12-15	1995-12-15
US008661		1995-12-15
PCT/EP1996/005362 WO1997022587A1 (en)	1995-12-15	1996-12-03	Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors

Publications (2)

Publication Number	Publication Date
BR9612136A true BR9612136A (pt)	1999-07-13
BR9612136B1 BR9612136B1 (pt)	2010-11-30

Family

ID=21732933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9612136-0A BR9612136B1 (pt)	1995-12-15	1996-12-03	ácidos arilsulfonamido substituìdos por alfa como inibidores de tnf-alfa hidroxámicos, alfa- de matriz de metaloproteinase, bem como composição farmacêutica compreendendo os mesmos.

Country Status (27)

Country	Link
US (1)	US5770624A (pt)
EP (1)	EP0873312B1 (pt)
JP (1)	JP4112004B2 (pt)
KR (1)	KR100452941B1 (pt)
CN (1)	CN1173948C (pt)
AR (1)	AR005068A1 (pt)
AT (1)	ATE219058T1 (pt)
AU (1)	AU709489B2 (pt)
BR (1)	BR9612136B1 (pt)
CZ (1)	CZ292431B6 (pt)
DE (1)	DE69621830T2 (pt)
DK (1)	DK0873312T3 (pt)
EA (1)	EA002019B1 (pt)
ES (1)	ES2178724T3 (pt)
HK (1)	HK1011536A1 (pt)
HU (1)	HU226123B1 (pt)
IL (1)	IL124524A (pt)
MX (1)	MX9804793A (pt)
NO (1)	NO311643B1 (pt)
NZ (1)	NZ324287A (pt)
PL (1)	PL187136B1 (pt)
PT (1)	PT873312E (pt)
SK (1)	SK78998A3 (pt)
TR (1)	TR199801105T2 (pt)
TW (1)	TW453995B (pt)
WO (1)	WO1997022587A1 (pt)
ZA (1)	ZA9610532B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL134816A (en) *	1995-12-08	2003-02-12	Agouron Pharma	Substituted diarylether sulfonic acids and their preparation
US6500948B1 (en)	1995-12-08	2002-12-31	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US5962481A (en) *	1996-10-16	1999-10-05	American Cyanamid Company	Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5929097A (en) *	1996-10-16	1999-07-27	American Cyanamid Company	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en)	1996-10-16	2001-05-08	American Cyanamid Company	Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) *	1996-10-16	1999-11-02	American Cyanamid Company	Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en)	1996-10-16	2003-04-15	American Cyanamid Company	Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6174915B1 (en)	1997-03-25	2001-01-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) *	1996-10-24	1999-12-28	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US5985900A (en) *	1997-04-01	1999-11-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
IL127496A0 (en) *	1997-12-19	1999-10-28	Pfizer Prod Inc	The use of MMP inhibitors for the treatment of ocular angiogenesis
US6492394B1 (en) *	1998-12-22	2002-12-10	Syntex (U.S.A.) Llc	Sulfonamide hydroxamates
US20040122011A1 (en) *	1998-12-23	2004-06-24	Pharmacia Corporation	Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
EP1147085B1 (en)	1999-01-27	2005-11-16	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
GB9918684D0 (en) *	1999-08-09	1999-10-13	Novartis Ag	Organic compounds
GB9922825D0 (en) *	1999-09-25	1999-11-24	Smithkline Beecham Biolog	Medical use
US6531128B1 (en) *	2000-02-08	2003-03-11	Pharmacia Corporation	Methods for treating glaucoma
EP1267903A4 (en) *	2000-02-08	2003-08-06	Pharmacia Corp	METHODS OF TREATING GLAUCOMA
US6465508B1 (en)	2000-02-25	2002-10-15	Wyeth	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
HUP0300235A2 (hu)	2000-03-21	2003-08-28	The Procter & Gamble Co.	Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0109348A (pt) *	2000-03-21	2003-06-10	Procter & Gamble	Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
EP1265865A2 (en)	2000-03-21	2002-12-18	The Procter & Gamble Company	Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
SK13362002A3 (sk) *	2000-03-21	2003-04-01	The Procter & Gamble Company	Metalloproteázové inhibítory zahŕňajúce vedľajší karbocyklický reťazec
BR0213736A (pt)	2001-11-01	2004-10-19	Wyeth Corp	ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
PE20030701A1 (es) *	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
GB0208176D0 (en) *	2002-04-09	2002-05-22	Novartis Ag	Organic compounds
AU2003253346A1 (en) *	2002-07-29	2004-02-23	Novartis Ag	Use or arylsulfonamido-substituted hydroxamid acid matrix metalloproteinase inhibitors for the treatment or prevention of toxemia
AU2003294917A1 (en) *	2002-12-20	2004-07-14	Novartis Ag	Device and method for delivering mmp inhibitors
WO2005021489A2 (en)	2002-12-23	2005-03-10	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
US8231858B2 (en)	2003-02-10	2012-07-31	Ge Healthcare Limited	Diagnostic imaging agents with MMP inhibitory activity
WO2004071384A2 (en) *	2003-02-11	2004-08-26	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions based on anticholinergics and tace-inhibitors
EP2041181B1 (en) *	2006-06-08	2011-05-18	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Specific protease inhibitors and their use in cancer therapy
FR2947270B1 (fr)	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr)	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en)	2013-03-15	2014-09-18	Galderma Research & Development	Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
EP3199534B1 (en)	2016-02-01	2018-09-05	Galderma Research & Development	Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
GB201621907D0 (en)	2016-12-21	2017-02-01	Ucb Biopharma Sprl And Sanofi	Antibody epitope

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552419A (en) *	1993-01-06	1996-09-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) *	1993-01-06	1997-07-08	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamix acids
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
EP0766664B1 (en) *	1994-06-22	2000-04-05	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives

1996
- 1996-11-26 TW TW085114549A patent/TW453995B/zh not_active IP Right Cessation
- 1996-12-03 AT AT96942307T patent/ATE219058T1/de not_active IP Right Cessation
- 1996-12-03 WO PCT/EP1996/005362 patent/WO1997022587A1/en active IP Right Grant
- 1996-12-03 HU HU0000214A patent/HU226123B1/hu not_active IP Right Cessation
- 1996-12-03 JP JP52245797A patent/JP4112004B2/ja not_active Expired - Fee Related
- 1996-12-03 EP EP96942307A patent/EP0873312B1/en not_active Expired - Lifetime
- 1996-12-03 DK DK96942307T patent/DK0873312T3/da active
- 1996-12-03 IL IL12452496A patent/IL124524A/en not_active IP Right Cessation
- 1996-12-03 NZ NZ324287A patent/NZ324287A/en unknown
- 1996-12-03 SK SK789-98A patent/SK78998A3/sk unknown
- 1996-12-03 ES ES96942307T patent/ES2178724T3/es not_active Expired - Lifetime
- 1996-12-03 PT PT96942307T patent/PT873312E/pt unknown
- 1996-12-03 CZ CZ19981854A patent/CZ292431B6/cs not_active IP Right Cessation
- 1996-12-03 KR KR10-1998-0704349A patent/KR100452941B1/ko not_active IP Right Cessation
- 1996-12-03 TR TR1998/01105T patent/TR199801105T2/xx unknown
- 1996-12-03 BR BRPI9612136-0A patent/BR9612136B1/pt not_active IP Right Cessation
- 1996-12-03 DE DE69621830T patent/DE69621830T2/de not_active Expired - Lifetime
- 1996-12-03 CN CNB961990171A patent/CN1173948C/zh not_active Expired - Fee Related
- 1996-12-03 EA EA199800529A patent/EA002019B1/ru not_active IP Right Cessation
- 1996-12-03 AU AU11406/97A patent/AU709489B2/en not_active Ceased
- 1996-12-03 PL PL96327450A patent/PL187136B1/pl not_active IP Right Cessation
- 1996-12-10 US US08/763,273 patent/US5770624A/en not_active Expired - Lifetime
- 1996-12-13 AR ARP960105665A patent/AR005068A1/es unknown
- 1996-12-13 ZA ZA9610532A patent/ZA9610532B/xx unknown
1998
- 1998-06-05 NO NO19982579A patent/NO311643B1/no unknown
- 1998-06-15 MX MX9804793A patent/MX9804793A/es not_active IP Right Cessation
- 1998-12-02 HK HK98112699A patent/HK1011536A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO982579L (no)	1998-06-05
NZ324287A (en)	1999-10-28
CZ185498A3 (cs)	1998-09-16
HUP0000214A2 (hu)	2000-09-28
KR20000064373A (ko)	2000-11-06
SK78998A3 (en)	1999-02-11
NO982579D0 (no)	1998-06-05
PL327450A1 (en)	1998-12-07
HU226123B1 (en)	2008-04-28
MX9804793A (es)	1998-10-31
ES2178724T3 (es)	2003-01-01
ATE219058T1 (de)	2002-06-15
EA199800529A1 (ru)	1999-02-25
CN1204320A (zh)	1999-01-06
IL124524A (en)	2002-12-01
NO311643B1 (no)	2001-12-27
PT873312E (pt)	2002-11-29
IL124524A0 (en)	1998-12-06
KR100452941B1 (ko)	2004-12-31
DE69621830D1 (en)	2002-07-18
EA002019B1 (ru)	2001-12-24
TW453995B (en)	2001-09-11
CN1173948C (zh)	2004-11-03
TR199801105T2 (xx)	1998-08-21
WO1997022587A1 (en)	1997-06-26
AR005068A1 (es)	1999-04-07
JP2000502088A (ja)	2000-02-22
HK1011536A1 (en)	1999-07-16
CZ292431B6 (cs)	2003-09-17
PL187136B1 (pl)	2004-05-31
AU1140697A (en)	1997-07-14
US5770624A (en)	1998-06-23
AU709489B2 (en)	1999-08-26
DK0873312T3 (da)	2002-10-07
HUP0000214A3 (en)	2000-10-30
JP4112004B2 (ja)	2008-07-02
EP0873312B1 (en)	2002-06-12
BR9612136B1 (pt)	2010-11-30
EP0873312A1 (en)	1998-10-28
DE69621830T2 (de)	2003-01-09
ZA9610532B (en)	1997-10-24

Publication	Publication Date	Title
BR9612136A (pt)	1999-07-13	Acidos hidroxâmicos arilsulfonamido substituídos por alfa como tnf-alfa e inibidores de metaloproteínase de matriz
DE69632321D1 (de)	2004-06-03	Schrittmachersystem zur verringerung des defilibrationsschwellenwertes
FR2751987B1 (fr)	1998-12-31	Phytases de plantes et applications biotechnologiques
PT966436E (pt)	2003-03-31	Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
BR9510175A (pt)	1997-10-14	Inibidores contendo ácido hidroxâmico de metaloproteases de matriz
DE69630947D1 (de)	2004-01-15	Mittel zur schmerzbehandlung
NO962889D0 (no)	1996-07-09	Kontakslös aktiv temperatursensor
TR199600516A2 (tr)	1996-08-21	Kakaonun enzimatik muamelesi.
DK0977733T3 (da)	2003-11-24	Arylsulfonylaminohydroxamsyrederivater
DE69820524D1 (de)	2004-01-29	Magnetisches Element und Magnetkopf oder Speicherelement die dieses Element verwenden
IT1271266B (it)	1997-05-27	Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
PT934259E (pt)	2003-01-31	Acidos beta-sulfonamido hidroxamicos como inibidores de metaloproteinases de matriz e de tace
BR9608773A (pt)	1999-07-06	Tratamento bacteriano para silagem
NL1003096C2 (nl)	1996-11-19	Application of phospholipases in animal feed.
EE200000093A (et)	2000-12-15	Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
BR9506883A (pt)	1997-08-19	Gene dna recombinante bactéria corineforme processos para produzir l-lizina e para produzir ácido l-glutâmico
ATE346090T1 (de)	2006-12-15	Abgeschwaechte mikroorganismen fuer die behandlung von infektionen
EP1018976A4 (en)	2000-11-22	Head-only animal exposure chambers
DK0888044T3 (da)	2002-02-18	Dyreøremærke
PT923530E (pt)	2004-12-31	Inibicao de metaloproteases de matriz por acidos biaril oxibutiricos substituidos
MA23769A1 (fr)	1996-10-01	Accumulation amplifiee de trehalose dans des plantes
DE69819858D1 (de)	2003-12-24	Membrane und Speicher der diese verwendet
ID17999A (id)	1998-02-19	Amida-amida asam alpha-amino, permbuatan dan penggunaannya secara terapi
NO982927D0 (no)	1998-06-23	Biologisk aktive benzotiazolon etanaminer
FR2786100B1 (fr)	2002-03-01	Nouvelle application therapeutique de la nicergoline

Legal Events

Date	Code	Title	Description
2005-09-06	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2006-01-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2006-06-13	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2006-10-24	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: INDEFIRO O PRESENTE PEDIDO POR NAO ATENDER AO DISPOSTO NOS ARTIGOS 24 E 25 DA LPI 9.279/96
2007-01-23	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2010-11-30	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/11/2010, OBSERVADAS AS CONDICOES LEGAIS.
2012-05-02	B24C	Patent annual fee: request for for restoration	Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 15A ANUIDADE.
2013-04-24	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE AO DESPACHO 24.3 PUBLICADO NA RPI 2156 DE 02/05/2012.